Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study.

Erica S. Tsang,Janine Marie Davies,Jonathan M. Loree,Howard John Lim,Daniel John Renouf,Sharlene Gill

Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study.

2020

Erica S. Tsang
Janine Marie Davies
Jonathan M. Loree
Howard John Lim
Daniel John Renouf
Sharlene Gill

491Background: Evidence supporting second-line therapies has become available for aHCC, including regorafenib, cabozantinib, ramucirumab, and nivolumab. The optimal second-line treatment regimen is...

Keywords:

Second-line therapy
Hepatocellular carcinoma
Cancer
Internal medicine
Medicine
population based
Oncology
Pathology
Nivolumab
in patient
Cabozantinib
Ramucirumab
population based study
Regorafenib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations